Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509380-24-00

Enrollment

Registered

2024-04-03

Start date

2021-11-01

Completion date

Unknown

Last updated

2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic upper gastrointestinal cancer, cancer of esophagus and stomach

Brief summary

Interferon gamma (IFN-ϒ) expression and number of infiltrating cytotoxic T-cells

Detailed description

 Overall survival  Progression-free survival  Response rate according to RECIST 1.1 or iRECIST  Adverse events according to NCI CTCAE version 5.0.  Quality of life  Percentage of patients proceeding to subsequent lines of treatment after progression and describe the types of subsequent treatments  Reasons for forgoing subsequent treatment after progression

Interventions

DRUGRetifanlimab (INCMGA00012)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Interferon gamma (IFN-ϒ) expression and number of infiltrating cytotoxic T-cells	—

Secondary

Measure	Time frame
 Overall survival  Progression-free survival  Response rate according to RECIST 1.1 or iRECIST  Adverse events according to NCI CTCAE version 5.0.  Quality of life  Percentage of patients proceeding to subsequent lines of treatment after progression and describe the types of subsequent treatments  Reasons for forgoing subsequent treatment after progression	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026